Maternal type 1 diabetes causes heart defects.

Published Date: 02 Mar 2023

A review of more than 600,000 Finnish births from 2006 to 2016 found that mothers with type 1 diabetes had more than four times as many children born with heart defects.

Read Full News

Latest News

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD Kassandra Holzem, MD

Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

Apremilast Effective Treatment for Moderate to Severe Genital Psoriasis at 32 Weeks

Apremilast Effective Treatment for Moderate to Severe Genital Psoriasis at 32 Weeks

FDA Proposes Expanding Active Ingredient List for Sunscreens

FDA Proposes Expanding Active Ingredient List for Sunscreens

Todays Updates

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Todays Updates

NeurologyLive® Brain Games: December 14, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Latest News

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

Apremilast Effective Treatment for Moderate to Severe Genital Psoriasis at 32 Weeks

FDA Proposes Expanding Active Ingredient List for Sunscreens

News All Time

8 Dermatology Headlines You Missed in November 2025

8 Dermatology Headlines You Missed in November 2025

Antibiotic Exposure Linked to Increased Risk of Biologic Discontinuation in Psoriasis

Antibiotic Exposure Linked to Increased Risk of Biologic Discontinuation in Psoriasis

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA

INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals

INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Lebrikizumab Benefits AD Patients With Skin of Color, With Vinay Mehta, MD Vinay Mehta, MD

New ACAAI 2025 data show lebrikizumab improves disease control, quality of life, and work productivity in patients of skin of color with moderate to severe atopic dermatitis.

Lebrikizumab Effectively Treats AD in Patients with Skin of Color, With Vinay Mehta, MD Vinay Mehta, MD

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

Discussing New Topical Drugs for Atopic Dermatitis in Younger Patients, With Peter Lio, MD Peter Lio, MD

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

The Medical Sisterhood: Balance and Boundaries in the Holiday Season, With Angela Lamb, MD Mona Shahriari, MD, FAAD, Angela Lamb, MD

In this episode, the topic of navigating the holiday season and balancing a thriving medical career and a fulfilling family life are highlighted.

Skin of Color Savvy: Hair-Care Challenges in Dermatology, With Amy McMichael, MD, and Kayla Taylor, MD Amy McMichael, MD, Kayla Taylor, MD

This November 18 episode explores early detection, diagnosis, and management of scarring alopecias and hair-care–related hair loss in patients of color.

Non-Steroidal Topicals: A Game-Changer for Pediatric Atopic Dermatitis, With Emily Becker, MD Emily Becker, MD

Becker recapped hot topics of discussion during a recent HCPLive clinical forum.

AI’s Use in Non-Patient-Facing Dermatology Spaces, With Joseph Gatti, DMSc, MPAS, MBA, PA-C

AI’s Use in Non-Patient-Facing Dermatology Spaces, With Joseph Gatti, DMSc, MPAS, MBA, PA-C

Recommended News For You

Surgery may not be necessary to treat invasive breast cancer

Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Exercise could ease symptoms for people with chronic lymphocytic leukemia, support and guidance are lacking: Study

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

An effective treatment for a rare but deadly form of cancer

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy

Recommended Articles For You

Liquid Biopsy in SCLC: cfDNA Profiling for Diagnosis and Treatment Monitoring 

Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics 

Colorectal Cancer Uncovered: CME, Case Studies, and Clinical Strategies 

Interpreting Iron Studies: What Your Blood Results Really Mean  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

2.

Scientists discover the 'roadmap' that aggressive cancer uses to spread

3.

Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.

4.

Metastatic breast cancer can be effectively treated with cyclical estrogen and anti-estrogen therapy.

5.

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.

1.

Unlocking the Potential of Elotuzumab: A Promising New Cancer Treatment

2.

Emerging and Innovative Therapies in Cancer Treatment and Post-Surgical Care

3.

Neutrophil Profiling and AI Rewrites Cancer Diagnosis

4.

Angina Haemorrhagica Bullosa: What You Need to Know

5.

Targeted Therapy: Latest Advances, Learning Tools, Trials & Treatment Options Explained

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

2.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

4.

CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC

5.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot